Trade Summary

1 week ago, Lynx1 Capital Management LP, serving as 10% owner at Tscan Therapeutics, Inc. (TCRX), purchased 161,801 shares at $0.90 per share, for a total transaction value of $145,526.00. Following this transaction, Lynx1 Capital Management LP now holds 15,956,564 shares of TCRX.

This purchase represents a 1.00% increase in Lynx1 Capital Management LP's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, December 19, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 23, 2025, 4 days after the trade was made.

Tscan Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.